BioCentury | Jul 7, 2008
Finance

Ebb & Flow

...79-4980 . The rFVIII formulated with pegylated liposome technology from Zilip Pharma, a subsidiary of Recoly...
BioCentury | Feb 12, 2007
Product Development

Doubling up for half-life

...79-4980 is a rFVIII formulated with pegylated liposome technology from Zilip Pharma, a subsidiary of Recoly N.V....
BioCentury | May 29, 2006
Clinical News

BAY 79-4980 hematology data

...subsidiary of Recoly. Data were presented at the World Federation of Hemophilia meeting in Vancouver. Recoly N.V....
BioCentury | May 29, 2006
Clinical News

BAY 79-4980: Phase I data

...subsidiary of Recoly. Data were presented at the World Federation of Hemophilia meeting in Vancouver. Recoly N.V....
Items per page:
1 - 4 of 4
BioCentury | Jul 7, 2008
Finance

Ebb & Flow

...79-4980 . The rFVIII formulated with pegylated liposome technology from Zilip Pharma, a subsidiary of Recoly...
BioCentury | Feb 12, 2007
Product Development

Doubling up for half-life

...79-4980 is a rFVIII formulated with pegylated liposome technology from Zilip Pharma, a subsidiary of Recoly N.V....
BioCentury | May 29, 2006
Clinical News

BAY 79-4980 hematology data

...subsidiary of Recoly. Data were presented at the World Federation of Hemophilia meeting in Vancouver. Recoly N.V....
BioCentury | May 29, 2006
Clinical News

BAY 79-4980: Phase I data

...subsidiary of Recoly. Data were presented at the World Federation of Hemophilia meeting in Vancouver. Recoly N.V....
Items per page:
1 - 4 of 4